Medicaid Drug Rebate Dispute Resolution Could Be Improved.

摘要

This review presents information collected from selected States and manufacturers related to preventing and resolving disputes. In addition, we collected information from CMS on its role in helping States prevent and resolve disputes. See Appendix A for a detailed methodology. Sample State selection. To determine the extent to which rebates are disputed under the Medicaid drug rebate program, we collected data from 31 States. These States indicated that they had the capability to provide all of the data that the OIG planned to request. Initially, we surveyed all States and the District of Columbia (hereinafter referred to as States) about their ability to provide data such as the amount of money ever in dispute, the amount of money currently in dispute, and the total amount of money invoiced since the rebate program began. Thirty-one States indicated that they could provide all of the requested information, and 20 States indicated that they could not.